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CLINICAL AND POPULATION STUDIES
Causal Associations Between Serum Bilirubin 
Levels and Decreased Stroke Risk
A Two-Sample Mendelian Randomization Study
Yoonjeong Choi,* Sun Ju Lee,* Wes Spiller, Keum Ji Jung, Ji-Young Lee, Heejin Kimm, Joung Hwan Back, Sunmi Lee, Sun Ha Jee
OBJECTIVE: A number of epidemiological studies have reported that decreased serum bilirubin, an endogenous antioxidant, 
is associated with cardiovascular disease. However, previous Mendelian randomization analyses conducted using a single 
sample have shown no evidence of association.
APPROACH AND RESULTS: A 2-sample summary Mendelian randomization study was performed by obtaining exposure and 
outcome data from separate nonoverlapping samples. We utilized data from the KoGES (Korean Genome and Epidemiology 
Study; n=25 406) and KCPS-II (Korean Cancer Prevention Study-II; n=14 541) biobank for serum bilirubin and stroke, 
respectively. Using KoGES, a total of 1784 single nucleotide polymorphisms associated with serum bilirubin levels were 
discovered using a genome-wide significance threshold (P<5×10−8), of which 10 single nucleotide polymorphisms were 
identified as independent (R2<0.005) and adopted as genetic instruments. From KCPS-II, total and ischemic stroke cases 
were identified (n=1489 and n=686), with 12 366 acting as controls. Various 2-sample summary Mendelian randomization 
methods were employed, with Mendelian randomization estimates showing an inverse causal association between serum 
bilirubin levels and total stroke risk (odds ratio, 0.481 [95% CI, 0.234–0.988]; P=0.046). This association increased in 
magnitude when restricting the analysis to ischemic stroke cases (odds ratio, 0.302 [95% CI, 0.105–0.868]; P=0.026).
CONCLUSIONS: Our findings provide evidence of significant causal relationship between high levels of bilirubin and decreased 
stroke risk in Korean population in agreement with observational approaches. This highlights the potential for bilirubin to 
serve as a therapeutic target for oxidative stress-related diseases such as stroke and suggests that previous findings were 
not a consequence of unmeasured confounding.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: bilirubin ◼ cardiovascular diseases ◼ causality ◼ single nucleotide polymorphism ◼ stroke
Serum circulating bilirubin is widely known as a secondary degradation product of heme, which is released from the breakdown of aging red blood 
cells.1 Under physiological conditions, unconjugated 
plasma bilirubin concentrations in humans typically 
range from ≈5 to 17 µmol/L.2 Abnormally high concen-
trations of bilirubin are considered toxic and are linked 
to clinical symptoms of kernicterus3 or neurological 
dysfunction due to the deposition of bilirubin in the 
brain.2 However, mild to moderately elevated serum bili-
rubin concentrations can serve as a potent endogenous 
antioxidant, through the process of bilirubin oxidizing 
itself to biliverdin.1,4 This is supported by studies find-
ing concentrations of total serum bilirubin <7 µmol/L 
to be a risk factor for oxidative stress-related diseases 
in humans, such as cardiovascular disease, diabetes 
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mellitus, metabolic syndrome, certain cancers, and 
autoimmune diseases.4
Stroke is one such form of oxidative stress-related 
disease5–7 and has been widely reported to be inversely 
associated with serum bilirubin levels in both Western8,9 
and Asian populations.10,11 However, such findings could 
result from unmeasured confounding factors, and as a 
consequence may not represent a true causal relation-
ship. One strategy to correct for bias due to unmeasured 
confounding is Mendelian randomization (MR), which 
uses genetic variants associated with an exposure of 
interest to estimate the effect of genetically predicted 
serum bilirubin on stroke risk. This has the potential to 
provide unbiased causal association estimates, provided 
genetic variants are associated with the exposure of 
interest (IV1), are independent of confounders of the 
exposure and outcome (IV2), and are independent of the 
outcome after conditioning on the exposure (IV3). Asso-
ciations violating assumptions IV2 and IV3 are generally 
referred to as horizontal pleiotropic associations.
In previous work, we performed a single sample MR 
analysis within a Korean population (n=5599), with esti-
mates suggesting a possible inverse association between 
serum bilirubin and total stroke risk (hazard ratio, 0.63 [95% 
CI, 0.30–1.33]; P=0.229).12 However, the sample size 
proved insufficient to provide sufficient statistical power to 
identify a causal relationship between serum bilirubin and 
total stroke risk at conventional significance thresholds.
Our previous study provided motivation to conduct a 
2-sample summary MR study, using data from the KoGES 
(Korean Genome and Epidemiology Study; n=25 406) and 
KCPS-II (Korean Cancer Prevention Study-II; n=13 855). 
By using 2 nonoverlapping samples, it has been possible 
to increase the sample size by a factor of 7 in compari-
son to our previous study. Further, adopting the 2-sample 
MR framework allows for several sensitivity analyses to 
be performed, critically examining the underlying assump-
tions of the MR approach (IV1-IV3). In this present study, 
we re-examine whether elevated serum bilirubin levels 
are causally associated with decreased stroke risk using 
2-sample summary MR, interpreting the findings within 
the context of previous observational and MR studies.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Selection of the Genetic Instrumental Variables
Candidate genetic instruments for total serum bilirubin levels 
were selected from KoGES. KoGES is a community-based 
cohort study, collecting data on ≈210 000 individuals from 
2005 to 2014. From the KoGES cohort, 33 598 participants 
were initially selected with both genetic and phenotypic data, 
comprising 13 108 men and 20 490 women aged from 40 to 
77. Among the 33 598 participants with genetic data, 25 406 
participants were finally selected who had measures of serum 
bilirubin levels. Serum total bilirubin levels (both direct and indi-
rect bilirubin) were measured through automated biochemical 
profiling, and the unit of bilirubin concentration was milligram 
per deciliter. General characteristics of KoGES population are 
shown in Table I in the online-only Data Supplement and further 
details concerning the KoGES can be obtained from the previ-
ously published cohort profile.13
Genetic data were obtained using the Korea Biobank Array 
(referred to as Korean Chip) available through the K-CHIP 
consortium. Korean Chip, containing about 830 000 single 
nucleotide polymorphisms (SNPs) specific to the Korean popu-
lation, was designed by the Center for Genome Science, Korea 
National Institute of Health, Korea (4845-301, 3000–3031).14 
Standard quality control procedures (P value for Hardy-
Weinberg equilibrium ≥1.0×10−6, call rate ≥95%, and INFO 
≥0.8) were used. Genetic data were imputed using SHAPEIT 
v.215 and Minimac v.3,16 utilizing the 1000 Genome reference 
panel phase 3, as well as 397 samples of Korean reference 
genome provided by the Center for Genome Science of Korea 
National Institute of Health.
We performed a genome-wide association study (GWAS) 
to identify SNPs associated with serum total bilirubin levels, 
adjusting for age and sex (minor allele frequency ≥0.01, P value 
for Hardy-Weinberg equilibrium test ≥0.0001). The GWAS of 
bilirubin was conducted without any transformation. The results 
Nonstandard Abbreviations and Acronyms
Chr chromosome
EA effect allele
GWAS genome-wide association study
ICAM-1 intercellular adhesion molecule 1
IVW inverse-variance weighted
KCPS-II Korean Cancer Prevention Study-II
KoGES Korean Genome and Epidemiology Study
Ldlr–/–  low-density lipoprotein receptor-deficient 
mice
MR Mendelian randomization
N SNPs the numbers of SNPs
OR odds ratio
SNP single nucleotide polymorphism
VCAM-1 vascular cell adhesion molecule 1
Highlights
• This Mendelian Randomization study revealed that 
serum bilirubin level is causally associated with 
decreased stroke risk.
• A magnitude of association became stronger when 
the outcome is limited to ischemic stroke.
• Bilirubin may be suggested as a potential therapeu-
tic target to the oxidative stress-related diseases, 
such as stroke.
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are presented in Figure I in the online-only Data Supplement. 
Applying a Bonferroni multiple testing correction, a total of 
1784 SNPs were identified to associated with serum total bili-
rubin levels at a genome-wide significance level (P<5×10−8). 
As 2-sample MR analyses generally require SNPs to be inde-
pendent, we applied a linkage disequilibrium clumping algorithm 
to identify independent SNPs using an R2 threshold <0.005. 
After excluding correlated SNPs by clumping algorithm, a total 
of 10 SNPs were selected as genetic instruments for geneti-
cally determined serum bilirubin levels.
A replication of the bilirubin GWAS was also performed 
using the KCPS-II biobank (n=13 855), and the Human Gene 
Ontology names of the 10 SNPs were explored from NCBI 
or PhenoScanner database.17 Cross-referencing identified 
SNPs using online data resources such as PhenoScanner is 
valuable in evaluating agreement with previous GWAS analy-
ses, as well as potentially highlighting associations which may 
violate the underlying MR assumptions. However, it should be 
acknowledged that as such resources are largely represen-
tative of Western populations, the extent to which they are 
applicable to non-Western populations must be taken into 
consideration.
Potential horizontal pleiotropic associations, violating 
assumptions IV2 and IV3 of the MR approach, were explored 
from the PhenoScanner database.17 We defined a SNP below 
GWAS significance (P<5×10−8, proxies for East Asian: R2>0.8) 
as being potentially pleiotropic, if the related phenotype had 
previously been reported as a cardiovascular risk factor.
Data Sources for the Study Outcome
Total and ischemic stroke were selected as outcome variables, 
using data from the KCPS-II biobank. KCPS-II is comprised 
of 156 701 individuals who visited 18 health examination cen-
ters in the Seoul and Gyeonggi districts of Korea for a health 
check-up from 2004 to 2013. The participants were aged 
from 20 to 84, including 94 840 men and 61 861 women. 
Further details about KCPS-II biobank are presented in a pre-
viously reported cohort profile,18 and general characteristics of 
KCPS-II population are displayed in Table I in the online-only 
Data Supplement. As with the KoGES sample, genetic data 
were produced using Korean Chip, using identical quality con-
trol and imputation methods.
Total stroke was defined as all forms of stroke including 
ischemic, hemorrhagic, and all other stroke subtypes, includ-
ing both prevalent and incident cases of stroke. International 
Classification of Diseases-Tenth Revision codes were used to 
define stroke and stroke subtype cases, specifically: ischemic 
stroke, I63–I639; hemorrhagic stroke, I60–I629; and all stroke 
types, I60–I699.
Stroke cases were determined using hospital admission 
discharge records from 2005 to 2015 (median follow-up dura-
tion, 8.0 years), available from health insurance claims provided 
by the National Health Insurance Service.10 A total of 1489 
total stroke cases were identified (654 ischemic stroke, 340 
hemorrhagic stroke, 32 ischemic-hemorrhagic combined 
stroke, and 463 all other stroke subtypes), and 686 ischemic 
stroke (654 ischemic stroke and 32 ischemic-hemorrhagic 
combined stroke). To conduct a GWAS of stroke risk, 12 366 
controls were used, fitting a logistic regression model adjust-
ing for age and sex (minor allele frequency ≥0.01, P value for 
Hardy-Weinberg equilibrium test ≥0.0001). Log odds for stroke 
risk were then used in subsequent MR analyses.
Signed written consent was obtained from all participants, 
and The Institutional Review Board of Yonsei University approved 
this study protocol (IRB approval number 4-2014-1008).
Statistical Analysis
For each individual genetic instrument, an MR estimate can 
be obtained by dividing the instrument-outcome association 
(KCPS-II) by the instrument-exposure association (KoGES). 
This is referred to as a Wald ratio estimate, using associa-
tion estimates obtained from GWASs. In this study, we spe-
cifically consider inverse variance weighted (IVW), MR-Egger, 
and weighted median regression approaches, which utilize the 
set of Wald ratio estimates provide more accurate estimates of 
causal effect, as well as test and correct for bias due to horizon-
tal pleiotropic pathways.
The IVW estimate is obtained by regressing the set of instru-
ment-outcome associations upon the instrument-exposure 
associations omitting an intercept and weighting each esti-
mate by the inverse of the variance of the instrument-outcome 
association. This represents a weighted average of Wald ratio 
estimates. In the case of MR-Egger regression, an intercept 
is included, interpreting the intercept as an average horizontal 
pleiotropic effect across the set of genetic instruments and the 
slope of the regression as the corrected causal effect.19
It should be noted that as an additional parameter is esti-
mated, MR-Egger is statistically less powerful than IVW. 
MR-Egger regression is also reliant on the magnitude of pleio-
tropic effects being independent of the strength of instrument-
exposure association. Finally, weighted median regression 
essentially calculates a weighted median using the Wald ratio 
estimates, with the weighting corresponding to the inverse vari-
ance weights selected. This has the advantage of being robust 
to bias due to horizontal pleiotropic bias, provided the propor-
tion of nonpleiotropic SNPs exceeds 50% with respect to their 
corresponding weighting.
Genetic instruments are required to be strongly associated 
with the exposure of interest (IV1), with the strength of asso-
ciation quantified using the F-statistic for the genetic instru-
ment in a regression of the exposure on the instrument. We 
calculate F-statistics adopting the method put forward by Au 
Yeung et al.20 The mean F-statistics for the 10 genetic instru-
ments was 168, satisfying the threshold of F>10, typically 
recommended for MR analyses.21 For reference, an F-statistic 
of 10 represents a relative bias of 10% toward the null in a 
2-sample MR setting.
Initially, Wald ratio estimates using each of the 10 genetic 
instruments were constructed by dividing the log odds of stroke 
risk by the β coefficient of bilirubin levels, obtained from GWASs 
of KCPS-II and KoGES. With this complete, IVW, MR-Egger, 
and weighted median regression models were applied, inter-
preting the estimated association as the effect of a genetically 
determined 1 mg/dL increase in serum bilirubin levels on the 
stroke risk.22 Additionally, we performed leave-one-out analy-
ses by systematically removing each SNP in turn and repeating 
the IVW analysis to assess if a single SNP is driving the asso-
ciation.23 For the MR-Egger regression, a significant nonzero 
intercept is considered evidence of horizontal pleiotropic bias 
(P value for MR-Egger intercept <0.05), and where this is not 
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the case, the IVW estimate is preferable owing to the statistical 
power limitations of MR-Egger regression.
To improve the visualization of the IVW and MR-Egger esti-
mates, we performed radial variants of the IVW and MR-Egger 
models. These models are similar to the conventional IVW and 
MR-Egger regression models, but regress the product of the 
Wald ratio estimate and the square root of the weighting for 
each genetic variant upon the square root of the genetic vari-
ants weighting. For radial IVW, an intercept is omitted in con-
trast to radial MR-Egger, as in the conventional setting. This 
has the advantage that genetic instruments which are subject 
to pleiotropic bias can be identified as outliers, based on their 
distance from the regression line. The distance of each point 
to the regression line is proportional to the individual contribu-
tion to global heterogeneity in effect estimates for the given 
genetic instrument.24
All MR analyses were calculated using the TwoSampleMR25 
and RadialMR24 R packages, using R, version 3.5.1 (R 
Development Core Team, Vienna, Austria).
RESULTS
Genetic Instrumental Variables for Bilirubin
The associations for each genetic instrument with serum 
bilirubin levels and stroke risk are presented in Table 1, 
and all genetic instruments were replicated within 
KCPS-II biobank participants (Table II in the online-only 
Data Supplement). Of the 10 genetic instruments, only 
rs2119503 had a readily identifiable pleiotropic associa-
tion, having previously been reported to be associated with 
Crohn disease in European populations (P=1.94×10−12). 
A proxy variant for rs2119503, rs6758317,26 was also 
associated with Crohn disease in East Asian populations 
(P=4.50×10−21).27 Although all instrumental variables 
were located on the chromosome 2 or 12, there was no 
overlap in terms of overarching gene. The associations of 
stroke risk for each genetic variant are shown in Table 1 
on the log odds scale.
Mendelian Randomization Analyses for Stroke 
Risk
IVW, MR-Egger, and weighted median regression were 
used to estimate causal associations between geneti-
cally predicted serum bilirubin levels and stroke risk 
(Table 2; Figure 1). Using IVW, we found evidence of 
causal relationships between bilirubin levels and stroke 
risk. Serum bilirubin levels seem to be negatively associ-
ated with both total and ischemic stroke risk (total stroke: 
IVW odds ratio [OR] per 1 mg/dL increase in serum 
bilirubin=0.481 [95% CI, 0.234–0.988]; P=0.046; Isch-
emic stroke: IVW OR per 1 mg/dL increase in serum 
bilirubin=0.302 [95% CI, 0.105–0.868]; P=0.026). MR-
Egger and weighted median regression also showed 
directionally similar estimates, though they seem insuf-
ficiently powered to exceed conventional significance 
thresholds (total stroke: MR-Egger OR per 1 mg/dL 
increase in serum bilirubin, 0.534 [95% CI, 0.125–2.286]; 
P=0.422; weighted median OR per 1 mg/dL increase in 
serum bilirubin, 0.469 [95% CI, 0.174–1.262]; P=0.134; 
ischemic stroke: MR-Egger OR per 1 mg/dL increase in 
serum bilirubin, 0.320 [95% CI, 0.037–2.781]; P=0.332; 
weighted median OR per 1 mg/dL increase in serum bili-
rubin, 0.430 [95% CI, 0.102–1.821]; P=0.252).
Funnel plots display the individual Wald ratios for 
each SNP plotted against their precision, where asym-
metry is indicative of directional horizontal pleiotropy. 
It should be noted, however, that assessing funnel 
plots with respect to symmetry is difficult when using 
a small number of genetic instruments (Figure 2). The 
MR-Egger intercepts show no evidence for significant 
directional pleiotropy, for both total and ischemic stroke 
(P=0.877 and P=0.954, respectively; Table 2). These 
results suggest that directional pleiotropic effects are 
not present between bilirubin levels and either total or 
ischemic stroke risk.
Table 1. List of Genetic Instruments for Serum Bilirubin Levels and Log Odds Ratios of Stroke Risk by Each Instrumental 
SNPs (GWAS Significance with P<5×10−8 and linkage disequilibrium threshold with R2<0.005)
No. SNP Gene Chr. EA OA EAF Bilirubin β (SE)
Total stroke loge OR 
(SE)
Ischemic stroke loge 
OR (SE)
1 rs12993249 USP40 2 G A 0.378 0.060 (0.003) 0.016 (0.041) 0.007 (0.060)
2 rs12996139 MSL3P1 2 A C 0.104 0.033 (0.004) −0.002 (0.065) −0.022 (0.094)
3 rs187332311 UGT1A12P 2 A G 0.024 0.058 (0.009) −0.033 (0.131) −0.175 (0.201)
4 rs2119503* ATG16L1 2 A G 0.117 0.053 (0.004) 0.026 (0.062) 0.023 (0.088)
5 rs4149014 SLCO1B1 12 G T 0.228 −0.024 (0.003) 0.040 (0.047) 0.036 (0.067)
6 rs4663344 TRPM8 2 T G 0.380 −0.015 (0.003) 0.043 (0.041) 0.079 (0.059)
7 rs55686299 MROH2A 2 G T 0.065 0.048 (0.005) 0.010 (0.081) −0.016 (0.118)
8 rs55986512 – 12 A G 0.089 0.062 (0.005) −0.171 (0.075) −0.233 (0.111)
9 rs6723506 UGT1A1 2 G A 0.027 0.169 (0.008) −0.226 (0.137) −0.445 (0.214)
10 rs73233620 SLCO1B3 12 G T 0.199 0.057 (0.003) −0.072 (0.051) −0.065 (0.074)
Chr indicates chromosome; EA, effect allele; OA, other allele; EAF, effect allele frequency; and OR, odds ratio.
*rs2119503 previously had known potentially pleiotropic effect related to Crohn disease.
Choi et al Causal Association Between Bilirubin and Stroke
Arterioscler Thromb Vasc Biol. 2020;40:437–445. DOI: 10.1161/ATVBAHA.119.313055 February 2020  441
CLINICAL AND POPULATION 
STUDIES - AL
Effects of Individual Genetic Instruments in 
Relation to Stroke Risk
To compare the influence of individual SNPs on the over-
all causal estimate, we performed leave-one-out analy-
ses. When we systematically removed each SNP and 
repeated the MR analyses, there did not appear to be 
a substantial difference in estimated causal effect. It is 
therefore likely that estimated effects are not the result 
of a single genetic instrument (Figure II in the online-only 
Data Supplement).
When using radial IVW and MR-Egger approaches, 
there did not appear to be evidence of outlying genetic 
variants. This result is in agreement with the leave-one-
out and MR-Egger analyses, which provide no indication 
of pleiotropic effects which could bias the overall analy-
ses (Figure 3).
DISCUSSION
In this present study, we revealed that genetically deter-
mined serum total bilirubin levels are causally associated 
with decreased total stroke risk in a Korean population. 
This association increased in magnitude when restricting 
the analysis to ischemic stroke cases.
A number of observational studies in humans have 
shown evidence of strong associations between serum 
bilirubin levels and cardiovascular diseases. For example, 
serum total bilirubin concentrations were negatively cor-
related to arterial stiffness in Chinese men.28 Likewise, 
serum bilirubin levels were observed to be inversely 
associated with coronary artery calcification and car-
diovascular events in a German population.29 In Chinese 
populations, serum total bilirubin levels were negatively 
associated with silent cerebral infarction, which increases 
Table 2. Mendelian Randomization for Serum Bilirubin on Stroke Risk
Total Stroke Ischemic Stroke
OR Estimates* (95% CI) P-Value N SNPs OR Estimates† (95% CI) P-Value N SNPs
IVW 0.481 (0.234–0.988) 0.046 10 0.302 (0.105–0.868) 0.026 10
MR-Egger regression 0.534 (0.125–2.286) 0.422 10 0.320 (0.037–2.781) 0.332 10
 Intercept† −0.006 (0.037) 0.877  −0.003 (0.055) 0.954  
Weighted Median 0.469 (0.174–1.262) 0.134 10 0.430 (0.102–1.821) 0.252 10
IVW indicates inverse-variance weighted; N SNPs, the numbers of SNPs; and OR, odds ratio.
*Odds ratio per 1 mg/dL increase in serum total bilirubin.
†Intercept is presented as β coefficients with SEs.
Figure 1. Scatter plot to visualize causal effect of serum bilirubin on total stroke risk (A) and ischemic stroke risk (B).  
The slope of the straight line indicates the magnitude of the causal association. IVW indicates inverse-variance weighted; and MR, Mendelian 
randomization.
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the risk of transient ischemia attack, symptomatic stroke, 
and cardiovascular diseases.30 Regarding stroke risk, 
one National Health and Nutrition Examination Survey 
1999 to 2004 study in the United States reported that 
serum total bilirubin levels were inversely associated with 
prevalent stroke and adverse stroke outcomes.9 In the 
Korean population specifically, serum bilirubin concen-
trations were estimated to be negatively associated with 
ischemic stroke in men.10
Using 2-sample summary MR, we investigated the 
causal relationship between circulating serum bilirubin 
levels and stroke risk. Interestingly, we found that genet-
ically increased bilirubin levels are causally associated 
with decreased total stroke risk. When we limited the 
outcome to ischemic stroke, the magnitude of relevance 
became stronger. These results are consistent with 
previous observational studies and support the argu-
ment that previous MR studies lacked statistical power 
to detect such associations. As previous MR studies 
showed evidence of the inverse association, albeit with 
P values exceeding conventional thresholds, we strongly 
support the argument put forward by Davey Smith and 
Sterne,31 that findings should be interpreted with respect 
to the context of the study, and not be reduced to arbi-
trary thresholds.
Several experimental studies also support our find-
ings. Vogel et al32 have revealed that bilirubin pre-
vents atherosclerotic lesion formation in low-density 
lipoprotein receptor-deficient mice (Ldlr−/−) by inhibiting 
endothelial VCAM-1 (vascular cell adhesion molecule 1) 
and ICAM-1 (intercellular adhesion molecule 1)-medi-
ated leukocyte migration. During atherosclerotic patho-
physiology, binding of leukocyte integrins to endothelial 
VCAM-1 and ICAM-1 generates cellular reactive oxygen 
species production. These reactive oxygen species lead 
to alterations in the endothelial junctional structure that 
facilitate the transmigration of leukocytes. But bilirubin, a 
potent antioxidant, can remove the reactive oxygen spe-
cies induced by the VCAM-1 and ICAM-1 activation that 
finally inhibit a migration of leukocyte and atherosclerotic 
lesion formation. This study group also has reported that 
bilirubin suppresses the transendothelial migration of 
murine lymphocytes in vitro33 and also attenuates tissue 
injury in mouse models of VCAM-1-dependent inflam-
mation.34 Another study group has also suggested that 
bilirubin has antiproliferative effects on vascular smooth 
muscle cells in vitro through p53-dependent cell cycle 
arrest by hypophosphorylation of the retinoblastoma 
tumor suppressor protein in growth factor–stimulated 
vascular smooth muscle cells.35 Collectively, the putative 
biological mechanisms linking serum bilirubin to stroke 
risk are bilirubin-mediated inhibition of lipid oxidation, 
immune cell migration, and vascular cell proliferation.36
The present 2-sample summary MR has several 
strengths compared with one-sample MR. First, in 
2-sample MR design, exposure and outcome variables 
Figure 2. Funnel plots to visualize overall heterogeneity of Mendelian randomization (MR) estimates for the effect of bilirubin 
on the total stroke (A) or ischemic stroke risk (B).  
IVW indicates inverse-variance weighted.
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are extracted from 2 independent populations, respec-
tively. This is advantageous in cases where exposure 
and outcome data are not available in the same set of 
individuals.37 In this study, serum bilirubin levels were 
measured in KoGES, but stroke cases were not fol-
lowed in this population. However, using stroke cases 
in the KCPS-II biobank, a homogenous population in 
terms of ethnicity and demographic profile, MR analyses 
could be performed. Further, utilizing multiple samples 
improves the overall sample size and subsequent preci-
sion of causal effect estimates. As a consequence, we 
were able identify a causal association between bilirubin 
levels and decreased stroke risk where our previous one-
sample MR study was unable.12 The 2-sample summary 
MR approach is also useful in not restricting researchers 
to using individual level data. In this study, summary esti-
mates were extracted from available individual level data; 
however, the methods can be applied in principle using 
publicly available GWAS data, as demonstrated by the 
MR-Base online platform.38
Two sample summary MR also has several charac-
teristics which improve upon analyses using a single 
sample. In cases where the instrument is not strong, vio-
lating the first MR assumption (IV1), effect estimates 
will be attenuated toward the null. This provides a more 
conservative estimate, as opposed to the one-sample 
setting in which weak instruments result in bias toward 
the observational estimate. A related advantage with 
respect to the underlying MR assumptions is that the 
2-sample study design is ideal for sensitivity analyses 
such as MR-Egger regression. As such, in performing 
a 2-sample summary MR, it is possible to perform a 
greater range of sensitivity analyses and arrive at more 
robust estimates of causal effect.
There are several limitations to this study. First, due 
to using summary data, any potential nonlinear relation-
ships or stratification effects cannot be explored. Sev-
eral previous epidemiological studies have argued that 
the association between bilirubin and cardiovascular risk 
resembles a U-shape39,40 and differs by sex.10,28,40 How-
ever, our previous work using quintile grouping by biliru-
bin level showed inversely linear associations between 
bilirubin and ischemic stroke risk in men, whereas all 
stroke cases showed no evidence of association. This 
result suggests that the observed U-shape association 
could potentially be driven by epidemiological studies 
failing to account for subtypes of CVD.10 Second, the 
absence of horizontal pleiotropic pathways is difficult to 
assess and if violated would result in biased estimates 
using IVW regression. We used MR-Egger and weighted 
Figure 3. Radial plots to visualize individual outlier single nucleotide polymorphisms (SNPs) in the Mendelian randomization 
(MR) estimates for total stroke (A) or ischemic stroke risk (B).  
Black dots show valid SNPs and green dots display invalid outlier SNPs. There is no significant outlier SNP in these present plots. IVW 
indicates inverse-variance weighted.
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median approaches to test for pleiotropic effects; how-
ever, each approach relies on a set of assumptions which 
are, at present untestable. Pleiotropic could be present 
where a majority of genetic instruments exhibit similar 
bias or where the instrument strength is associated with 
the magnitude of pleiotropic effect. The absence of outli-
ers supports these assumptions holding, though the pos-
sibility cannot be discounted.
As a third limitation, the clumping algorithm used to 
identify correlated genetic variants relied primarily on 
European samples from the 1000 genomes project. This 
is owing to the lack of corresponding data for East Asian 
populations. However, as none of the genetic instru-
ments shared a common gene, it seems probable that 
the conventional clumping algorithm is sufficient in this 
case. This is further supported by the inclusion of SNPs 
located on the UGT1A1 and SLCO1B1 genes, which 
encode essential proteins for the bilirubin metabolism. 
This shows that the genetic variants selected remain bio-
logically plausible. Finally, it is important to emphasize that 
as this study focuses solely upon effects within a Korean 
population, the results cannot be immediately general-
ized to other ethnicities without further justification.
CONCLUSIONS
In summary, we have shown evidence of causal rela-
tionships between circulating serum bilirubin levels 
and decreased stroke risk in Korean population. These 
results support the conclusions of previous observational 
studies between bilirubin and oxidative stress-related 
diseases such as stroke and atherosclerosis. This study 
therefore contributes to a growing body of evidence sug-
gesting bilirubin could play a role as a therapeutic target 
to cardiovascular diseases.
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